Is Anthem Biosciences IPO a risky bet for investors?



Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit have increased, the company faces geographical and client concentration risks.

Comments